Table 6.
Interaction | Treatments | Total antioxidant capacity (mmol/L) | Superoxide dismutase (U/mL) | Glutathione peroxidase (μmol/L) | Malondialdehyde (nmol/mL) |
---|---|---|---|---|---|
Day 17 | Control | 6.56d | 67.44c | 1,024.90d | 18.15d |
CP | 3.32e | 59.31d | 800.29e | 28.22a | |
CA | 10.77b | 78.56a | 1,319.53b | 12.69e | |
CA + CP | 7.44d | 69.88b,c | 1,191.34c | 16.81d | |
AB | 6.60d | 66.42c,d | 1,017.16d | 18.70c,d | |
AB + CP | 6.36d | 66.77c | 1,049.87d | 18.37d | |
Day 21 | Control | 9.83b,c | 66.91c | 1,140.70c,d | 23.63b |
CP | 1.66f | 59.15d | 570.73f | 30.06a | |
CA | 19.20a | 79.46a | 1,533.56a | 13.80e | |
CA + CP | 9.68b,c | 73.60b | 1,351.62b | 21.01c | |
AB | 9.74b,c | 64.16c,d | 1,083.82c,d | 23.50b | |
AB + CP | 8.96c | 61.90d | 1,040.70d | 25.77b | |
SEM | 0.472 | 1.642 | 39.716 | 0.825 | |
Stage | |||||
Day 17 | 6.84b | 68.06 | 1,067.18b | 18.82b | |
Day 21 | 9.84a | 67.53 | 1,120.19a | 22.96a | |
SEM | 0.193 | 0.670 | 16.214 | 0.337 | |
Treatments | |||||
Control | 8.20b | 67.18c | 1,082.80c | 20.89b | |
CP | 2.49c | 59.23d | 685.51d | 29.14a | |
CA | 14.98a | 79.01a | 1,426.54a | 13.24d | |
CA + CP | 8.56b | 71.74b | 1,271.48b | 18.91c | |
AB | 8.17b | 65.29c | 1,050.49c | 21.10b | |
AB + CP | 7.66b | 64.34c | 1,045.28c | 22.07b | |
SEM | 0.334 | 1.161 | 28.083 | 0.584 | |
P-values | |||||
Stage | <0.001 | 0.577 | 0.027 | <0.001 | |
Treatments | <0.001 | <0.001 | <0.001 | <0.001 | |
Stage × Treatments | <0.001 | 0.196 | <0.001 | 0.005 |
In the same line, the same letter superscripts mean no significant difference (P > 0.05), and the different letter superscripts mean significant difference (P < 0.05).
Abbreviations: AB, antibiotic group; AB + CP, antibiotic + C. perfringens group; CA, chlorogenic acid group; CA + CP, chlorogenic acid + C. perfringens group; CP, Clostridium perfringens group; SPF, specific-pathogen-free.